{"id":"NCT03764735","sponsor":"Mitotech, SA","briefTitle":"Study of SkQ1 as Treatment for Dry-eye Syndrome","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution for the Treatment of Dry Eye Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-06","primaryCompletion":"2019-02-09","completion":"2019-02-09","firstPosted":"2018-12-05","resultsPosted":"2022-01-19","lastUpdate":"2022-01-19"},"enrollment":452,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndrome"],"interventions":[{"type":"DRUG","name":"Low Dose - SkQ1","otherNames":["Visomitin"]},{"type":"DRUG","name":"High dose - SkQ1","otherNames":["Visomitin"]},{"type":"DRUG","name":"SkQ1 (Vehicle)","otherNames":[]}],"arms":[{"label":"SkQ1 Vehicle","type":"PLACEBO_COMPARATOR"},{"label":"Low Dose - SkQ1","type":"ACTIVE_COMPARATOR"},{"label":"High Dose - SkQ1","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.","primaryOutcome":{"measure":"Central Corneal Staining Change From Baseline","timeFrame":"From baseline to Day 57","effectByArm":[{"arm":"SkQ1 Vehicle","deltaMin":-0.28,"sd":0.773},{"arm":"Low Dose - SkQ1","deltaMin":-0.3,"sd":0.816},{"arm":"High Dose - SkQ1","deltaMin":-0.2,"sd":0.763}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":151},"commonTop":["Instillation site pain","Visual acuity reduced"]}}